67results about How to "Reduce Biosecurity Risks" patented technology

The invention discloses a full-process biological detection device, belonging to the technical field of biological detection. The a full-process biological detection device comprises at least one reactor, wherein the reactor comprises at least one sample adding unit, at least one controlled liquid release unit, at least one extraction unit, at least one controlled liquid switching unit, at least one liquid storage unit, at least one liquid transfer unit, at least one liquid flow control unit, at least one quantitative liquid dispersion unit and a plurality of reaction tanks, wherein all the above units communicate with each other through runners according to a preset sequence, and when the reactor rotates around a chip rotating shaft, liquid in the reactor can flow to downstream unit fromupstream unit through the runners under the driving of centrifugal force or surface tension or both the centrifugal force and the surface tension. The full-process biological detection device providedby such a scheme has the characteristics of high integration level, no need for additional reagents, simplicity in operation, stability, reliability and the like, realizes full-flow closing of a target during biological detection, and effectively avoids cross contamination between samples and equipment.

In order to solve the problems that some biological products are poor in stability, cannot be stored at normal temperature, cannot be well stored easily and are not convenient to use in emergency circumstances such as a disaster, the invention relates to a porous frame material creatively applied to biomolecule storage, and the stability and other performances are improved. The porous frame material and biomolecules are used for forming a porous frame material / biomolecule compound, the biomolecule is wrapped, and therefore the protection effect is achieved. On the premise of keeping the biomolecule activity, the system can achieve efficient separation and recycling of porous materials and biomolecules. While a biological product protecting system is developed, various performances are comprehensively detected and evaluated, the technical purposes of synthesis, storage, release and the like are solved, the good technical effect is achieved, the biomolecules can be effectively protected,and the material is used for storing a biological agent and preparing novel preparations.

The invention provides a prepared clostridium septicum CSA genetic engineering vaccine, which is optimized by a codon and is produced by recombinant clostridium septicum CSA (rCSAM4 delta 11) obtainedby deleting 11 amino acids (212th bit to 222nd bit) on the basis of containing 4 amino acid mutations (C54L, N264A, H269A and W310A); the completeness and spatial conformation of the natural toxin are reserved to the maximum degree, so that the immunogenicity is maintained; the biological safety hazards due to minority amino acid mutation are avoided. Meanwhile, nontoxic rCSAM4 delta 11 can be expressed in a soluble form, so that the influence of the complicated process of the inclusion body denaturation and renaturation on antigen protein immunogenicity is avoided, and the preparation time and the production cost of the vaccine are reduced. In addition, the vaccine also has the advantages of low immunizing dose, good immunizing effect and the like, and belongs to an ideal candidate vaccine for upgrading and updating the existing clostridium septicum toxin vaccine.

The invention discloses a high immunogenicity rabies virus glycoprotein and its preparation method as well as application. The preparation method consists of: performing artificial synthesis to acquire an all dominant neutralization epitope-containing and codon optimized rabies virus glycoprotein gene, then taking a recombinant adenovirus, a recombinant baculovirus or a slow virus as an expression vector, and performing high-efficiency expression in a mammalian cell line, an insect cell line or a silkworm expression system, thus obtaining the rabies virus glycoprotein that has high immunogenicity to domestic epidemic rabies virus strains currently. And the high immunogenicity rabies virus glycoprotein is used for immunoprophylaxis of animal rabies.

The invention relates to a 2019-nCoV sampling tube, which comprises an inner tube of which the upper part is provided with an opening, wherein an outer tube which is integrally formed with the inner tube and is lower than the inner tube is fixedly arranged outside the inner tube in a sleeving mode; a buffer cavity is formed between the inner tube and the outer tube; the opening end of the inner tube is covered with a sealing cover; the sealing cover is provided with a piston through an adjusting mechanism, wherein the piston can be in plug-in sealing fit with the inner tube; the sealing cover is connected with a first connecting belt and a second connecting belt; the first connecting belt is connected with the outer tube; the second connecting belt is provided with a bayonet; and the second connecting belt is clamped with a bulge convexly arranged on the outer tube through the bayonet. The 2019-nCoV sampling tube can be effectively sealed, the sealing cover and the sampling tube are connected through the connecting belts, and cross contamination between samples can be avoided so as to guarantee that a detection result is accurate.

The invention relates to non-toxic tetanus toxin and clostridium novyi alpha toxin recombinant fusion protein. The prepared recombinant fusion protein is produced in the manner that The prepared recombinant fusion protein is produced in the manner that through codon optimization, a tetanus toxin C fragment, C terminal of clostridium novyi alpha toxin, and N-end non-toxic epitope of clostridium novyi alpha toxin are subjected to fusing expression, so that the immunogenicity of two kinds of toxin protein can be reserved to the maximum extent, and biology potential safety hazard of natural toxincan be avoided. The recombinant fusion protein can be used for preparing clostridium tetani and clostridium novyi subunit vaccines. Compared with the clostridium tetani and clostridium novyi subunit vaccines commercialized in China at present, the non-toxic tetanus toxin and clostridium novyi alpha toxin recombinant fusion protein has the advantages of being simpler in preparation technology, lower in immunizing dosage, better in vaccine effects and the like, the biology security risk in the production process of the vaccine is greatly reduced, and the non-toxic tetanus toxin and clostridium novyi alpha toxin recombinant fusion protein is an ideal candidate vaccine antigen for upgrading and regenerating two clostridial toxin vaccines. When the non-toxic tetanus toxin and clostridium novyialpha toxin recombinant fusion protein and other antigens are in jointed preparation of a combined vaccine, the using dosage of the combined vaccine does not need to be increased, and the combined vaccine can be prepared.

The invention relates to a nontoxic clostridium perfringens and clostridium septicum fusion protein vaccine and a production method thereof. The fusion protein vaccine prepared by the method adopts aclostridium perfringens epsilon toxin which is subjected to codon optimization and contains three amino acid mutations, and spoilage which contains four amino acid mutations and eleven amino acid deletions, namely not only kept the integrity and spatial conformation of the natural toxin are to the maximum extent, but also the biological safety hazard caused by single amino acid mutation is avoided. The vaccine also has the advantages of simple preparation process, excellent vaccine efficacy and the like, greatly reduces the biological safety risk in the vaccine production process. Compared with the current commercialized sheep fast-epidemic and sheep enterotoxemia inactivated vaccines in China, the vaccine is an ideal candidate vaccine for upgrading existing clostridium perfringens and clostridium septicum vaccines in China; in addition, when combined vaccines are prepared by the vaccine together with other antigens, the combined vaccine can be prepared without increasing the use doseof the combined vaccine.

The invention relates to the technical field of biology, in particular to a preserving solution for sputum and a preparation method. The preserving solution of each 1000ML comprises the following components: 0.5-3.5g of dithiothreitol, 5.0-30g of tris(hydroxymethyl)methyl aminomethane, 0.1-10.5g of sodium chloride, 0.01-2.0g of phosphorus trichloride, 0.01-2.5g of disodium hydrogen phosphate, 0.01-2.5g of potassium dihydrogen phosphate, 0.2-3.5g of guanidinium isothiocyanate and the balance nucleic acid-free water, and the pH value is 5.5-8.5. The preserving solution prepared by the inventioncan be stored and applied at room temperature, has a digesting / liquefying function, can effectively digest / liquefy specimens (sputum), does not need to digest the specimens before detection, and meanwhile, has an inactivation effect on specimen (sputum) viruses, so that the biosafety risk of specimen preservation, transportation, processing and detection is lowered; after being collected, sputum specimens collected by using the preserving solution can be stored for 72 hours at 2-8 DEG C, and can be stored for 10 days or more at ultra-low temperature (-70 DEG C); and moreover, the components ofthe preserving solution are easy to obtain, and the preparation cost is low.

The invention provides a goat contagious pleuropneumonia subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of preparation of animal infectious disease vaccines, and a mycoplasma capricolum subsp.capripneumonia immune protein combination comprises mycoplasma capricolum subsp.capripneumonia immune proteins A, B, C, D and E; the mass ratio of the mycoplasma capricolum subsp.capripneumoniae immune proteins A to B to C to D to E is (0.5 to 1.5): (0.5 to 1.5): (0.5 to 1.5): (0.5 to 1.5): (0.5 to 1.5); and the goat contagious pleuropneumonia subunit vaccine comprises the goat mycoplasma goat pneumonia subspecies immune protein combination and an adjuvant. The subunit vaccine has the advantages of high safety, good immune effect, good stability and small side reaction.